Exsurgo are please to announce the release of Axon in the UK. Richard Little, Exsurgo Chief Executive says “”When we embarked on the journey to create this product, we were driven by the singular vision of alleviating pain and enhancing the quality of life for millions. Today, we stand at a pivotal moment where that …
Exsurgo clincical partner Jon Graham, the Clinical Director of PhysioFunction UK, presented a Case Study of an Axon Patient to the Multidisciplinary Association for Spinal Cord Injury Professionals (MASCIP) conference on the 16th November this year. Read the Case Report
Exsurgo’s Chief Science Officer, Christine Ozilins presernted a Case Report poster at the International Neuromodulation Society conference in Hamburg, Germany that took place in early September this year. Read the Case Report
Exsurgo is proud to work with Homeless Shelter Micah House in Nebraska Read more…
With the tech scene currently booming in New Zealand, and with more and more innovative companies coming up every week, local creative business outlet, Idealog has outlined some of the companies they will be keeping an eye out on in 2023 including our very own Exsurgo. From financial ventures to breakthroughs in the health industry, …
Exsurgo has launched new study using EEG neurofeedback as a therapy to manage neuropathic pain in the United Kingdom. Funded by Exsurgo, the new trial is being led by researchers from the East Kent Hospitals University NHS Foundation Trust. Researchers are currently recruiting for ten patients who, over a 22 week period, will wear an …
East Kent chronic pain management medical trial launches in the UK Read More »
How gamification can support treatment for chronic pain and other neurological conditions Whether it’s smoking, drinking, eating unhealthy food or even mindlessly scrolling through social media, people can’t resist a quick hit of pleasure despite knowing the long-term pitfalls of such behaviour. Through a healthcare lens, this can be dangerous because many of us make …
Hi all, We are thrilled to share that our final trialist has completed the Active Neurofeedback Treatment phase of the New Zealand Axon trial in partnership with Auckland University of Technology (AUT) and Waitematā District Health Board (WDHB). As a random Controlled Clinical Trial, it is considered the ‘gold standard’ of clinical trials. The trial …
This article first appeared in NZBusiness Magazine. Richard Little is an inventor making traction in the treatment of chronic pain and other neurological conditions without the use of pharmaceuticals. Here he shares his lessons and advice for health tech entrepreneurs. Entrepreneurship is not a career path known for stable and steady progression. From crying in …
Our CEO and Co-founder Richard Little recently featured in the first of a three-part series by NBR’s Fiona Rotherham on the current challenges facing New Zealand’s healthtech sector. The key challenge facing the sector is the need for a national network of innovation hubs to help early-stage companies with funding, commercialisation, and research. This hub …
The challenges for NZ’s booming healthtech sector Read More »
